Tauopathies are a group of disorders in which the cytosolic protein tau aggregates and accumulates in cells within the brain, resulting in neurodegeneration. A promising treatment being explored for tauopathies is passive immunization with anti-tau antibodies. We previously found that administration of an anti-tau antibody to human tau transgenic mice increased the concentration of plasma tau. We further explored the effects of administering an anti-tau antibody on plasma tau. After peripheral administration of an anti-tau antibody to human patients with tauopathy and to mice expressing human tau in the central nervous system, there was a dose-dependent increase in plasma tau. In mouse plasma, we found that tau had a short half-life of 8 min that increased to more than 3 hours after administration of anti-tau antibody. As tau transgenic mice accumulated insoluble tau in the brain, brain soluble and interstitial fluid tau decreased. Administration of anti-tau antibody to tau transgenic mice that had decreased brain soluble tau and interstitial fluid tau resulted in an increase in plasma tau, but this increase was less than that observed in tau transgenic mice without these brain changes. Tau transgenic mice subjected to acute neuronal injury using 3-nitropropionic acid showed increased interstitial fluid tau and plasma tau. These data suggest that peripheral administration of an anti-tau antibody results in increased plasma tau, which correlates with the concentration of extracellular and soluble tau in the brain.
INTRODUCTION
Tauopathies, including Alzheimer's disease (AD), Down syndrome dementia, progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), Pick's disease, certain forms of frontotemporal lobar degeneration (FTLD), and chronic traumatic encephalopathy, are a group of neurodegenerative disorders characterized by the hyperphosphorylation and aggregation of the protein tau in the central nervous system (CNS) (1) . Tau is a cytosolic microtubule-associated protein that is localized primarily in neuronal axons under normal conditions (1) (2) (3) . Its aggregation in specific brain regions in different tauopathies is directly associated with neurodegeneration in those regions (4) (5) (6) (7) . Emerging evidence suggests that once tau aggregates in the specific brain regions that are characteristic for each tauopathy, pathological forms of tau then spread through synaptically connected neural networks (8, 9) .
Because tauopathies are currently untreatable, a variety of approaches have been taken attempting to target tau therapeutically. Despite the fact that tau is predominantly a cytosolic protein, it is normally released into the extracellular space from neural cells, and its release is regulated by excitatory neuronal activity (10, 11) . A number of studies in animal models have shown that both active and passive immunization targeting tau can have beneficial effects on reducing tau pathology and improving function (12) (13) (14) (15) (16) (17) (18) (19) . One mechanism that may account for these effects is via the ability of antibodies to block the intercellular spread of tau pathology. In recent studies, we found that a mouse monoclonal anti-tau antibody, HJ8.5, was able to block the cellular seeding activity of externally applied tau aggregates as well as decrease insoluble tau in the brain and improve function (12) . In exploring the potential mechanisms by which this anti-tau antibody might exert its effects, we found that peripheral administration of HJ8.5 to Tau transgenic (Tg) mice that express human tau (hTau) predominantly in the CNS markedly increased plasma tau (20) . This suggested that further exploration of the effects of anti-tau antibodies and plasma tau might provide insight into tau metabolism in the CNS.
To further determine both the origin of plasma tau and the potential use of plasma tau measurements as a marker of CNS tau, we assessed plasma tau concentrations before and after anti-tau antibody administration in a variety of mice expressing hTau and in human subjects with PSP. Here, we report that tau increased in the plasma of mice expressing hTau and in the plasma of PSP patients after administration of an anti-tau antibody.
RESULTS

Anti-tau antibody dose-dependently increases plasma tau in Tg mice and human patients with tauopathy
We previously assessed the effects of administering the mouse monoclonal anti-tau antibody HJ8.5 to P301S Tau Tg mice that developed tau pathology in the brain beginning at~5 to 6 months of age (21) . HJ8.5 is a high-affinity antibody specific to hTau that is directed to an epitope in the N terminus amino acids 25 to 30 (12) . In agreement with our previous report (20) , intraperitoneal administration of HJ8.5 at doses ranging from 10 to 200 mg/kg to 3-month-old P301S Tau Tg mice resulted in a large, dose-dependent increase in plasma tau 48 hours after antibody injection (Fig. 1A) . Plasma tau in Tg mice was assessed using single-molecule array (Simoa) technology, a digital enzyme-linked immunosorbent assay (ELISA) detection system developed by Quanterix (22, 23) . Given that HJ8.5 has strong effects on decreasing tau pathology and improving function when given chronically to P301S Tau Tg mice over months, a humanized version of HJ8.5 was developed as a potential treatment for tauopathies. It was administered to an individual with PSP as part of an expanded access treatment protocol. Several doses of the humanized antibody were administered monthly. Tau in human plasma was assessed using a plate-based human plasma tau ELISA (in contrast to the Simoa technology) both before dosing administration and after a dose of 7.5 mg/kg given intravenously. Consistent with peripheral administration of HJ8.5 to mice, intravenous administration of the humanized antibody to one PSP patient resulted in a robust increase in plasma tau (Fig. 1B) . Baseline plasma tau in this individual was not detectable with the human plasma tau assay used (lower limit of detection, 10 pg/ml) before antibody administration. After antibody administration, tau increased rapidly over 24 hours, with concentrations of tau reaching~250 pg/ml over several days (Fig. 1B) . This is about 60-fold higher than the amount of tau previously reported in human plasma by others (~4 pg/ml) using a more sensitive assay (24) . To confirm this observation, we also measured plasma tau in three additional participants receiving the same antibody in a phase 1 singledose study in subjects with PSP. These three individuals received a single dose of 15 mg/kg, and their plasma tau was assessed (Fig. 1C) . As with the first individual administered the antibody, baseline plasma tau was not detectable (<10 pg/ml) with the human plasma tau assay used. However, after antibody administration, plasma tau increased tõ 150 to 300 pg/ml after 7 to 14 days. Thus, consistent with our observations in Tg mice expressing hTau, plasma tau markedly increased 50-to 100-fold over baseline at the doses used after peripheral administration of an anti-tau antibody to humans.
Antibody-mediated increase in plasma tau half-life enables tau detection One possible mechanism by which tau antibodies could increase plasma tau is by altering the half-life of tau once it enters the plasma. To test this hypothesis, we injected recombinant hTau intravenously into the jugular vein of wild-type mice in the presence and absence of the anti-tau antibody HJ8.5 and assessed the clearance of tau from the plasma. Plasma tau was measured with the Simoa ELISA. We found that the half-life of intravenously injected hTau in plasma was 8.49 min (Fig. 2, A and D) . Administration of HJ8.5 [50 mg/kg intraperitoneally (ip)] 1 hour before jugular vein injection of recombinant hTau extended the half-life of tau to~3.4 hours (Fig. 2, B and D) . We next coincubated recombinant hTau with a 10-fold molar excess of HJ8.5 and administered the tau-antibody complex intravenously to wild-type mice. Coincubation of HJ8.5 with tau increased the half-life of tau within the plasma to an even greater extent of~13.2 hours (Fig. 2, C and D) . These data suggested that the peripheral administration of an anti-tau antibody increased plasma tau by binding to tau and extending the half-life of tau in the plasma (Fig. 2, B to D) .
To determine the extent to which tau in the extracellular space of the CNS enters the plasma and is measurable in the plasma, we injected recombinant hTau into the cisterna magna of wild-type mice in the presence or absence of peripherally administered HJ8.5. In control mice, plasma tau was detectable in the plasma within minutes after cisterna magna injection and exhibited a half-life of 1.6 hours (Fig.  2 , E and G). The increased half-life of CNS-injected tau versus venousinjected tau likely reflected continued entry of tau from the cerebrospinal fluid (CSF) into plasma over several hours after a single bolus injection. In HJ8.5-injected mice, hTau was detected in the plasma within minutes after CNS injection, but the half-life was increased to almost 24 hours (Fig. 2, F and G) . Again, this suggested that the HJ8.5-tau antibody complex had a prolonged half-life in plasma relative to tau alone, which likely accounted, at least in part, for the HJ8.5-dependent increase in plasma tau.
HJ8.5-induced increase in plasma tau occurs in different mouse models expressing hTau To further characterize the effects of HJ8.5 on plasma tau and to determine its origin, we administered HJ8.5 at a dose of 50 mg/kg ip to a variety of hTau Tg mice. P301S Tau Tg mice express hTau under the control of the prion promoter, which drives transgene expression Plasma tau was measured before the injection (prebleed) and 48 hours after antibody injection. Plasma tau measurements were analyzed using the Simoa HD-1 analyzer. **P ≤ 0.01 and ****P ≤ 0.0001, one-way analysis of variance (ANOVA) followed by Dunnett's post hoc test for multiple comparisons. (B) Humanized anti-tau antibody HJ8.5 at a dose of 7.5 mg/kg was intravenously injected into a single individual with PSP, and plasma tau was measured before (0-hour time point) and after antibody injection at various time intervals (1, 2, 4, 5, 14, and 28 days). (C) Humanized anti-tau antibody HJ8.5 at a dose of 15 mg/kg was intravenously injected into three human subjects with PSP, and plasma tau was measured before and after antibody injection. Tau was not detected with this assay before antibody injection. Human plasma samples were analyzed with a human plasma tau ELISA assay. n = 3 for each time point shown. Values represent means ± SEM. predominantly in the CNS, but also in peripheral tissues such as muscle. Therefore, plasma tau is likely to be detectable under basal conditions in P301S Tau Tg mice due to some expression of tau in peripheral tissues outside of the CNS (Fig. 3A) . We wanted to verify that the increase in plasma tau in Tg mice after HJ8.5 administration was attributable to CNS-derived tau. We administered HJ8.5 to two different mouse models: the hTau mouse, which expresses hTau under control of the endogenous tau promoter, and a mouse model in which adeno-associated virus (AAV) type 2/8 mediates brain expression of hTau under control of a neuronal-specific synapsin promoter (25) . We injected AAV 2/8-expressing human P301S tau (AAV-syn-P301S) intracerebroventricularly into the brain of postnatal day 0 (P0) wild-type mice. This resulted in strong CNS expression of hTau by 1 month of age, at levels comparable to those observed in 3-monthold P301S Tau Tg mice (Fig. 3B) . Unlike P301S Tau Tg mice, hTau was not detectable in the plasma of either 2-month-old hTau mice or 1-month-old AAV-tau mice under basal conditions (Fig. 3A) . Plasma tau in different Tg mice was assessed using Simoa technology. The lower limit of detection in the plasma tau Simoa assay we used in mice was~1 pg/ml. Injection with HJ8.5 increased plasma tau in hTau mice and AAV-tau mice to 93 pg/ml and~20 ng/ml, respectively (Fig. 3A) . Given the large difference between hTau and AAV-tau mice regarding plasma tau detected after HJ8.5 administration, we decided to measure soluble hTau in the mouse brain using a plate-based hTau-specific ELISA. We found that soluble tau was much lower in hTau mice compared to P301S and AAV-tau mice (Fig. 3C) , suggesting that the different plasma tau concentrations observed after HJ8.5 administration reflected different concentrations of soluble tau within the CNS compartment. However, because of major differences in the promoters used in these mice and both the amount and location of tau expression between the hTau-expressing mouse models, we decided to further test this idea in just one model.
HJ8
.5-induced increases in plasma tau correlate with soluble brain tau Given that we saw differences in plasma tau elevation upon antibody injection, which appeared to be potentially related to differences in soluble tau in the brain, we hypothesized that we might be able to . (E) hTau was injected into the cisterna magna of wild-type B6C3 mice (n = 6), and plasma was collected at 25 min and 1, 2, 3, and 6 hours. (F) Ten minutes after HJ8.5 antibody injection (50 mg/kg ip), hTau was injected into the cisterna magna of wildtype mice (n = 6), and plasma was collected at 10 min and 1, 6, 24, 48, and 72 hours. (G) Half-life of plasma tau after injection into the cisterna magna of wild-type mice in the absence (E) and presence of HJ8.5 (F). Tau half-life was calculated by determining the slope from linear regression fit of semilog plots of concentration versus time (41) . Values in (D) and (G) represent means ± SEM. *P ≤ 0.05, **P ≤ 0.01, and ***P ≤ 0.001. Values in (D) analyzed by ANOVA followed by post hoc Dunnett's test and values in (G) analyzed by unpaired t test.
detect pathology-dependent alterations in soluble tau using antibodydependent measurements in plasma tau. In previous studies, we characterized the amount of tau within the interstitial fluid (ISF) as well as brain soluble and insoluble tau in P301S Tau Tg mice (26) . ISF tau represents tau present in the extracellular space of the brain that is released from neurons (11) . It is only a small fraction of the soluble brain tau assessed biochemically, which is predominantly composed of cytosolic tau. In accordance with previous results, we observed an agedependent decline in soluble tau, an age-dependent increase in insoluble tau, and no age-dependent change in the detergent-containing radioimmunoprecipitation assay (RIPA) buffer solubilized tau (Fig. 4 , A to C). Furthermore, we found higher ISF tau in young, presymptomatic P301S mice compared to 9-month-old P301S mice (Fig. 4D ). The amount of ISF tau in 9-month-old mice was~60% lower than in 3-month-old mice. No changes were observed in total hTau expression by quantitative polymerase chain reaction (qPCR) (Fig. 4E) .
Having established that aged mice bearing tau pathology exhibited decreased total soluble and ISF tau, we next tested whether we would detect differences in antibody-dependent increases in plasma tau between P301S mice of different ages before and after the onset of tau pathology. After intraperitoneal injection of HJ8.5 (50 mg/kg), plasma tau assessed with the Simoa assay increased over 1 to 6 hours and remained elevated for more than a week compared to basal conditions in 3-, 6-, and 9-month-old P301S mice (Fig. 5 , A to C). As a control group, anti-human Ab antibody HJ3.4 (50 mg/kg) was injected into P301S Tau Tg mice. No change in plasma tau was observed in these groups (Fig. 5 , A to C). The amount of plasma tau in the HJ8.5-injected mice was decreased by 60% in the 9-month-old mice during the first 24 hours after HJ8.5 injection compared to the amount in the 3-and 6-month-old groups (Fig. 5, D and E). This result was in accordance with the observed decrease in total brain soluble tau and ISF tau in 9-month-old compared to 3-month-old P301S mice (Fig. 4 , A and D). To further investigate this relationship, we plotted the amount of plasma tau in HJ8.5-treated mice as a function of soluble brain tau and found a positive correlation between the amount of soluble brain tau and plasma tau (Fig. 5F ). Together, these results suggest that brain extracellular tau in ISF is in equilibrium with a biochemically extractable salt-soluble pool of tau within the brain and that the ISF pool of tau can enter plasma where it can be captured and detected by an anti-tau antibody.
Changes in mouse brain ISF tau and plasma tau detected by HJ8.5 after neuronal injury Although the data suggest that decreases in soluble brain tau and ISF tau that occur in 9-month-old versus 3-month-old P301S mice may be reflected in plasma after HJ8.5 injection, we wanted to determine whether injury-induced increases in extracellular tau could also be detected in the blood after peripheral injection of the anti-tau antibody. We decided to assess the effects of unilateral striatal infusion of a neuronal toxin, 3-nitropropionic acid (3-NP), on ISF tau. Baseline striatal ISF tau was assessed in a group of P301S Tau Tg mice followed by infusion of 3-NP through reverse microdialysis. This treatment resulted in a 10-to 20-fold increase in striatal ISF tau over several hours (Fig 6A) . We then stereotactically injected a group of P301S Tau Tg mice bilaterally with either 3-NP or PBS into the striatum, as previously described (27) . Four hours later, mice received an intraperitoneal injection of HJ8.5 (50 mg/kg). Plasma tau was assessed before and after 3-NP or PBS injection using the Simoa tau assay. Plasma tau increased in all mice administered HJ8.5 (Fig. 6B) . However, there was a significantly greater increase in plasma tau in mice given 3-NP compared to those given PBS (P < 0.01) (Fig. 6B ). This suggested that not only decreases but also increases in ISF tau could be detected in plasma after treatment with an anti-tau antibody.
DISCUSSION
Disease-modifying therapies, including immunotherapies, are emerging as potential treatments for neurodegenerative diseases. Antibodies targeting Ab are furthest along in this process (28) ; however, antibodies targeting tau and a-synuclein have also shown promising results in animal models and have entered clinical trials (29, 30) . A challenge moving forward in clinical trials for neurodegenerative diseases characterized by protein aggregation is screening for patients who have the aggregated form of the protein being targeted in the Fig. 3 . Increased plasma tau after HJ8.5 injection in different mouse models expressing hTau. (A) Plasma tau was analyzed before antibody injection (prebleed) and 48 hours after HJ8.5 injection in 2-month-old hTau mice (which express hTau under control of the endogenous tau promoter) (n = 5), 3-month-old P301S Tau Tg mice (n = 8), and 1-month-old wild-type mice injected with AAV vector expressing P301S hTau under control of the synapsin promoter (AAV-syn-P301S) (n = 8). ns, not significant. (B) Representative coronal brain sections stained with biotinylated anti-hTau antibody HJ8.5 from a 1-month-old (1M) mouse with AAV 2/8-mediated expression of P301S hTau under control of the synapsin promoter (AAV-syn-P301S), a 3-month-old P301S Tau Tg mouse (P301S), and a 1-month-old C57BL/6 wildtype mouse. Scale bar, 600 mm in length. (C) hTau measured by hTau-specific ELISA in brain cortical salt-containing RAB-soluble fractions from 2-month-old hTau mice, from 3-month-old P301S mice, and from 1-month-old AAV-syn-P301S mice (AAV). Values in (A) and (C) represent means ± SEM.
CNS and determining whether the therapy being used is hitting its target. Here, we found that peripheral administration of anti-tau antibody to mice expressing hTau and to humans with PSP resulted in a marked increase in plasma tau. Our data indicated that the antibodydependent increase of plasma tau resulted primarily from CNSderived tau and that plasma tau concentrations appeared to reflect soluble, extracellular tau in the brain. The results of this study in both humans and mouse models suggest a direct relationship between extracellular tau in the CNS and plasma tau.
Expression of tau is almost exclusively in neurons, where it is present in the cytosol. It is also released by neurons in the brain physiologically and can be detected in soluble forms in brain ISF and CSF (10, 11) . In brain ISF, tau has a long half-life (~11 days in mice) (31) . In human plasma, it is detectable in only low amounts (~4 pg/ml) in humans (24) . Our data suggest that when tau enters the plasma from the CNS, it is rapidly cleared (Fig. 2A) . In the presence of a tau antibody, tau that enters the plasma binds to the antibody, and this extends the plasma half-life of detectable tau (Fig. 2) . It is also possible that some antibodytau complexes form initially in the CNS and then are cleared via the plasma with normal clearance of antibody from the brain to the blood. Our data suggest that the amount of tau bound to anti-tau antibody in plasma is related to brain soluble tau and, perhaps more directly, to extracellular tau such as that in the ISF. For example, after neuronal injury, ISF tau and plasma tau both increased (Fig. 6) , possibly due to extracellular release of cytosolic tau in the brain after injury. In addition, we detected lower tau in the plasma of older P301S Tau Tg mice with tau pathology after anti-tau antibody administration reflecting lower ISF tau and brain soluble tau (Fig. 5) . Although there was a difference in salt-containing reassembly buffer (RAB)-soluble tau in mice before versus after establishment of tau pathology between age groups, there was no correlation between RAB-soluble tau and plasma tau after administration of anti-tau antibody within each age group. This may be similar to the observed relationship between CSF Ab 42 and amyloid deposition in the brains of human patients with AD pathology and mouse models of amyloidosis in which once Ab has aggregated, then CSF and ISF Ab 42 decrease (32-34). However, low CSF Ab 42 in individuals with amyloid deposition does not correlate with the absolute amount of Ab deposition within this group. Although CSF Ab 42 does not correlate with the absolute amount of amyloid deposition, it may be useful for clinical trial patient selection on the basis of its ability to discriminate between the presence and absence of amyloid deposition. Whether increases in plasma tau after anti-tau antibody administration would be different in humans with a primary tauopathy compared to healthy controls is currently not known but should be tested in future studies.
We and others have found that administration of certain anti-Ab antibodies results in a large increase in plasma Ab in both mice and humans that is predominantly derived from the brain (35) (36) (37) (38) (39) . The large increase in plasma Ab seen with certain antibodies may be due to a prolongation of plasma Ab half-life when bound to antibody, perhaps similar to what we report here with tau. Animal studies suggest that these changes in Ab may also reflect the amount of extracellular , and 70% FA-soluble hTau (C) are shown in 3-month-old (n = 10), 6-month-old (n = 15), and 9-month-old (n = 14) P301S Tau Tg mice. Ninemonth-old P301S mice had lower cortical RABsoluble and higher FA-soluble tau compared to 3-or 6-month-old P301S mice. **P ≤ 0.01 and ****P ≤ 0.0001,one-way ANOVA followed by post hoc Dunnett's test. (D) Soluble ISF hTau was measured by microdialysis in hippocampal tissue from 3-month-old (n = 9) and 9-month-old (n = 7) P301S mice that were not treated with an anti-tau antibody. Nine-month-old mice had lower ISF tau compared to 3-month-old mice. *P ≤ 0.05, twotailed t test. (E) hTau mRNA in cortex from 3-month-old (n = 10), 6-month-old (n = 14), and 9-month-old (n = 9) P301S Tau Tg mice. Tau mRNA was normalized to total complementary DNA (cDNA). hTau mRNA from 6-and 9-month-old P301S Tau Tg mice was normalized and compared to tau mRNA from 3-month-old P301S Tau Tg mice. No difference in hTau mRNA between the groups was observed (P > 0.05, one-way ANOVA post hoc Dunnett's test). Values represent means ± SEM.
soluble Ab in the CNS that is entering the blood (36, 39). Manipulations that alter brain-to-blood clearance of Ab, such as the brain expression of the low-density lipoprotein receptor, affect the concentration of Ab detectable in the blood after anti-Ab antibody administration (40) . However, there are differences between CNS-derived Ab and tau. The half-life of CNS-derived Ab in mice is~1.5 to 3 hours; the half-life of CNS-derived tau in mice is~11 days (31, 41) .
There are several limitations to this study. First, whether all antitau antibodies will increase plasma tau as we report here is not yet known, although others have also observed increases in serum tau after administration of different anti-tau antibodies to tau Tg mice (16, 42) . Second, the differences in plasma tau after anti-tau antibody administration that were observed in the presence or absence of tau pathology or after neuronal injury in mice have only been studied in one mouse model, the P301S Tau Tg mouse. Whether these differences will be observed in other animal models of tauopathy is not yet clear. Third, it is not yet known whether increases in plasma tau in PSP patients observed after the administration of the anti-hTau antibody used here will reflect brain extracellular tau. Given these limitations, because anti-tau antibodies have now moved forward into clinical trials, it will be important to assess plasma tau across different patient populations, including primary tauopathies, such as PSP, CBD, Pick's disease, chronic-traumatic encephalopathy, and FTLD caused by MAPT mutations, compared to AD in which there are both Ab and tau accumulation and changes in CSF tau. Notably, whereas CSF tau is elevated in AD and after acute neuronal injury, such as stroke or Fig. 5 . Anti-tau antibody mediated increases in plasma tau in P301S Tau Tg mice of different ages. Plasma tau was measured before (0-hour time point) and after intraperitoneal injection of HJ8.5 (50 mg/kg) or anti-human Ab antibody HJ3.4 (50 mg/kg) at 1, 6, 24, 72, and 168 hours in 3-month-old (A), 6-month-old (B), and 9-monthold (C) P301S Tau Tg mice (n = 10 to 15 mice per group). (D) Summary of data from panels (A) to (C) showing plasma tau measured in 3-month-old (black bars), 6-monthold (gray bars), and 9-month-old (red bars) P301S mice before (0-hour time point) and after HJ8.5 intraperitoneal injection. *P ≤ 0.05 and **P ≤ 0.01, two-way ANOVA with post hoc Dunnett's test. (E) Area under the curve (AUC) of plasma tau (pg/ml × hours) was calculated for the first 24 hours after HJ8.5 injection in 3-, 6-, and 9-month-old P301S mice. *P = 0.04 and **P = 0.004, two-tailed t test. Values represent means ± SEM. All plasma samples were analyzed on a Simoa HD-1 analyzer. (F) Positive correlation was seen between plasma tau 24 hours after HJ8.5 injection (y axis) and brain cortical RAB-soluble tau (x axis). Spearman r, r = 0.51; ***P = 0.0007. Red triangles, 3-monthold mice; blue circles, 6-month-old mice; black squares, 9-month-old mice. traumatic brain injury, compared to controls, CSF tau is not elevated in the primary tauopathy PSP. CSF tau is lower in PSP patients than in age-matched controls (43) (44) (45) .
A well-established observation is that there is an elevation of CSF tau in AD (46) . This is likely a completely different phenomenon than what takes place in primary tauopathies. In AD, CSF tau is likely elevated due to neuronal and synaptic membrane damage secondary to amyloid deposition, not directly due to tau aggregation. This was demonstrated in a recent study where it was shown that murine CSF tau is normal in young amyloid precursor protein Tg mice before amyloid deposition, but then progressively increases once amyloid deposition begins to accumulate in the brain (47) . Given that these mice do not develop neurofibrillary tangles or tau aggregation, it suggests that amyloid-linked neuronal/synaptic injury leads to an increase in ISF/ CSF tau release independent of tau aggregation. We report a similar phenomenon after acute brain injury in P301S Tau Tg mice. In this mouse model of acute CNS neuronal injury induced by striatal administration of 3-NP, we found an increase in brain ISF tau and also higher plasma tau after anti-tau antibody administration compared to mice without neuronal injury given the anti-tau antibody. Given these results, we would predict in patients with amyloid deposition and in individuals with acute brain injury from stroke or head trauma that there would be an increase in plasma tau compared to age-matched healthy controls after anti-tau antibody administration.
Given our findings, it will be important to determine whether differences in plasma tau after anti-tau antibody administration can be used to screen for individuals with primary tauopathies (where tau is the only major protein aggregating in the brain) or those with AD (where both Ab and tau aggregate in the brain). Finally, because anti-tau antibodies move forward into clinical trials, it will be important to determine whether a reduction in tau accumulation detected by tau imaging and any clinical response after anti-tau antibody therapy correlates with plasma tau measurements. In addition, understanding how plasma tau and CSF tau correlate before and after anti-tau antibody administration may also provide insights into the mechanism of action of anti-tau antibodies.
MATERIALS AND METHODS
Study design
The aim of this study was to assess concentrations of plasma tau in patients with PSP and in mouse models expressing hTau before and after administration of an anti-tau antibody. In mouse models, another goal was to determine the half-life of plasma tau in the presence and absence of the anti-tau antibody and any differences in plasma tau after antibody administration that were due to tau pathology. All mice and human subjects in this study were randomly assigned to experimental groups. All studies were performed by investigators blinded to treatment groups and sample identity. Replication numbers for experiments are listed in the figure legends.
Administration of humanized HJ8.5 antibody to patients with PSP The mouse monoclonal antibody was cloned from the hybridoma expressing HJ8.5, and the variable regions were cloned to a human immunoglobulin G (IgG4) Fc domain followed by humanization of several amino acids outside of the complementarity-determining region. A humanized version of HJ8.5 was administered to an individual with PSP following a treatment protocol under an expanded access program [expanded access Investigational New Drug (IND) 119404] by C 2 N Diagnostics. Informed consent was obtained from the individual, and all procedures were approved by an Institutional Review Board. The individual was administered multiple doses of the antibody once per month. Blood samples were collected at various time points before and after start of drug infusion for the purpose of measuring drug concentrations and biomarkers. The same antibody was also administered to individuals as part of a phase 1 single-dose study entitled "Safety, Tolerability, and Pharmacokinetics of C2N-8E12 in Subjects with Progressive Fig. 6 . Increased hTau in mouse plasma and ISF after anti-tau antibody administration after neuronal injury. (A) Soluble ISF hTau was measured by microdialysis in the striatum of 8-to 9-month-old P301S Tau Tg mice (n = 4). After stable baseline collection, the neurotoxin 3-NP was administered via reverse microdialysis for 3 hours, and ISF tau was measured. Injury to the mouse striatum caused an increase in ISF tau for 12 hours after 3-NP treatment. One-way ANOVA followed by post hoc Dunnett's test P < 0.05. (B) Four to 5-month-old P301S mice were injected bilaterally in the striatum with either PBS (n = 5) or 3-NP (n = 5, 100 mM). Four hours later, HJ8.5 at 50 mg/kg was administered intraperitoneally, and plasma tau was assessed before (0 hour) and after 3-NP or PBS injection at 24, 48, and 72 hours. Compared to PBS-treated P301S Tau Tg mice, there was an increase in plasma tau at 48 and 72 hours in P301S Tau Tg mice after 3-NP treatment (*P = 0.029 and **P < 0.01, two-way ANOVA with post hoc Dunnett's test).
Supranuclear Palsy," NCT02494024. Informed consent was obtained from all participants, and all procedures were approved by an Institutional Review Board.
Tau Tg mice and anti-tau antibody treatment All animal procedure and experiments were performed with the guidelines approved by the animal studies committee at Washington University School of Medicine. We used several different hTau Tg mice. P301S Tau Tg mice (the Jackson Laboratory) overexpress the human T34 isoform of hTau (1N4R) with the P301S mutation under the control of the prion promoter (21) . These mice are on B6C3 background and develop tau pathology by 5 to 6 months of age. hTau mice (male and female) that express all six isoforms of hTau but do not express mouse tau were used (25) . These mice develop hyperphosphorylated tau by 6 months of age (25) . For AAV injections, P0 pups of C57BL/6 mice were used. Pregnant C57BL/6 mice were purchased from Charles River Laboratories. Plasma was collected from 2-month-old hTau mice, 1-month-old AAV-injected mice, and 3-month-old male P301S Tau Tg mice 1 day before HJ8.5 injection and 48 hours after HJ8.5 (50 mg/kg) intraperitoneal injection. For dose-response experiments, 3-month-old male P301S mice were administered HJ8.5 by intraperitoneal injection at 10, 50, and 200 mg/kg. Control mice were administered PBS. All the plasma samples were stored at −80°C until use. For experiments involving P301S mice at different ages (3, 6, and 9 months old), only male mice were used, and plasma samples were collected 1 day before HJ8.5 injection and at various time intervals (1, 6, 24, 72, and 168 hours) after HJ8.5 (50 mg/kg) intraperitoneal injection. Anti-human Ab antibody HJ3.4 was used as control antibody. All plasma samples were stored at −80°C until use.
Administration of AAV vector into mouse brain P301S hTau was cloned from P301S Tg mouse cDNA and inserted into an AAV-synapsin driven promoter vector. AAV 2/8 serotype was produced at the Hope Center Viral Vectors Core (Washington University, St. Louis). C57BL/6 mice P0 pups were intraventricularly injected bilaterally with 2 ml (1 × 10 13 viral genome-containing particles per milliliters) of AAV 2/8 carrying hTau with the P301S mutation (AAV-P301S) under the control of the synapsin promoter using a 10-ml Hamilton syringe (Sigma-Aldrich). One month after viral infection, plasma was collected from tail bleeds 1 day before injection and 48 hours after an intraperitoneal injection of HJ8.5 (50 mg/kg). Plasma samples were stored at −80°C until use.
Collecting blood samples from mice Blood samples were collected at various time points from tail bleeds for Tg mice and retro-orbital bleeds for wild-type mice. Heparinized capillary tubes (Kimble Chase) were used to collect blood, which was transferred into 1.5-ml Eppendorf tubes along with 1 ml of 0.5 M EDTA. The last time point of blood collection was from anesthetized mice (50 mg/kg of sodium pentobarbital) from the right ventricle of the heart with a 1-ml insulin syringe filled with 20 ml of 0.5 M EDTA. Blood samples were spun at 8000 rpm (6000g) for 10 min at 4°C to obtain plasma. Plasma samples were stored at −80°C until use.
Measurements of plasma tau half-life in mice
For experiments involving assessment of hTau half-life in the plasma of mice, recombinant hTau (rPeptide) at 1 mg/100 ml of saline was injected into the jugular vein under isoflurane anesthesia in 3-month-old male B6C3 wild-type mice, and retro-orbital bleeds were collected at various time intervals (after 2, 4, 8, 12, 18, and 25 min). Recombinant hTau (1 mg; rPeptide) was preincubated at room temperature with 10 times molar excess of HJ8.5 (2.3 mM) and injected into the jugular vein of 3-month-old B6C3 wild-type mice. Plasma was collected from tail bleeds at different time intervals of 10 min and 6, 24, 48, and 72 hours. In some experiments, 1 mg of recombinant hTau was injected into the jugular vein 1 hour after intraperitoneal administration of HJ8.5 (50 mg/kg), and plasma was collected 10 min and 1, 6, and 24 hours after injection. To determine the half-life of hTau in plasma after administration into the cerebrospinal fluid in the cisterna magna, we anesthetized 3-month-old wild-type male B6C3 mice by intraperitoneal injection of xylazine (10 mg/kg)/ketamine (100 mg/kg) in normal saline. Then, mice were injected with recombinant hTau (2 mg/2 ml; rPeptide) into the cisterna magna compartment, as previously described (48) . Plasma was collected from tail bleeds at different time intervals of 25 min and 1, 2, 3, and 6 hours. For experiments in the presence of HJ8.5 antibody, 10 min after intraperitoneal injection of HJ8.5 (50 mg/kg), hTau was injected into the cisterna magna. Plasma was collected at various time intervals of 10 min and 1, 6, 24, 48, and 72 hours. All plasma samples were analyzed on Simoa HD-1 analyzer. Half-life of tau was calculated by first-order kinetics, determining the slope of linear regression from the semilog plot of concentration versus time. Elimination rate constant (K e ) and half-life (t 1/2 ) were calculated with K e = 2.0303/slope and t 1/2 = 0.693/K e , respectively, as previously described (11, 41, 49) .
Detection of hTau by immunohistochemistry
Immunostaining was performed as previously described (12) . To determine the expression of hTau in different Tg mice, we stained brain sections with biotinylated HJ8.5 antibody. For staining, three brain sections of 50-mm thickness and 300 mm apart corresponding approximately to sections at Bregma coordinates −1.4, −1.7, and −2.0 mm in the mouse brain atlas were used (50) . Brain sections were blocked with 3% milk in tris-buffered saline and 0.25% (v/v) Triton X followed by incubation overnight at 4°C with the biotinylated HJ8.5 antibody. C57BL/6 and B6C3 wild-type mice brain sections were used as negative controls.
Measurements of plasma tau using the Simoa assay in mice To measure tau in mouse plasma, we used a Simoa assay, a sensitive digital ELISA platform (51) . Homebrew assays specific for total tau were developed according to the manufacturer's recommendations (Quanterix Corp.). All plasma tau levels measurements were analyzed using the Simoa HD-1 analyzer (Quanterix Corp.). Simoa HD-1 consumables were purchased from Quanterix Corp. The paramagnetic beads were precoated with a mouse monoclonal antitau HJ8.7 capture antibody. In addition to the coated beads, diluted plasma samples, biotinylated detector anti-tau antibody BT2 (Pierce), streptavidin b-galactosidase, and enzyme substrate (resorufin b-Dgalactopyranoside) were added to the Simoa HD-1 analyzer. Recombinant hTau was included in each run to generate a standard curve. Assays were performed according to the manufacturer's instructions (Quanterix Corp.). The presence of HJ8.5 in this assay did not interfere with or influence the assay results.
ELISA assay for measuring plasma tau in PSP patients
To determine tau in human plasma samples, we used an ELISA in which plates were first coated with BT2 antibody (1 mg/ml) (Thermo Scientific) in PBS supplemented with 20% glycerol and left to incubate overnight at 4°C. The next day, plates were blocked with 2% bovine serum albumin (BSA) in PBS supplemented with Tween 20 0.05 and 20% glycerol for 2 hours at room temperature. Human plasma samples were diluted 1:5 in sample diluent [0.20% BSA, 300 mM tris (pH 8.0), 0.05% Tween 20, mouse IgG (mIgG) (20 mg/ml), 0.05% ProClin 300, and PBS], whereas the calibrator (recombinant tau 412, rPeptide) was prepared in calibrator diluent [0.20% BSA, 300 mM tris (pH 8.0), 0.05% Tween 20, mIgG (20 mg/ml), 20% pooled normal plasma samples, 0.05% ProClin 300, and PBS]. Calibrators and samples were incubated overnight at 4°C. The next day, plates were washed four times with PBS followed by incubation with biotinylated mouse monoclonal anti-tau antibody HJ8.7 (1 mg/ml) in 1% BSA in PBS for 2 hours at room temperature. Plates were then washed four times with PBS followed by incubation with streptavidin polyhorseradish peroxidase 40 (1:6000; Fitzgerald) for 1 hour at room temperature. Plates were washed four times with PBS and then developed with Super Slow ELISA TMB (3,3′,5,5′-tetramethylbenzidine) (SigmaAldrich), and the absorbance read at 650 nm.
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Biochemical extraction of mouse brain tissue
Biochemical extractions were performed as previously described (12) . Briefly, cortical brain samples were homogenized in RAB [30 ml/mg (v/w)] [(100 mM MES, 0.5 mM MgSO 4 , 1 mM EDTA, 2 mM dithiothreitol, 0.75 M NaCl, and 1 mM Na 3 VO 4 (pH 6.8)] and supplemented with 1× protease and phosphatase inhibitors (Roche). Samples were spun at 50,000g for 20 min, and the supernatant was saved as a RAB-soluble fraction. Pellet was dissolved in RIPA buffer [30 ml/mg (v/w)] (150 mM NaCl, 50 mM tris, 0.5% deoxycholic acid, 1% Triton X-100, 0.5% SDS, and 25 mM EDTA (pH 8.0)], supplemented with protease and phosphatase inhibitors (Roche), and spun at 50,000g for 20 min. The supernatant was collected as a RIPA-soluble fraction. The pellets were further dissolved in 70% formic acid (FA) at 10 ml/mg, sonicated, and centrifuged at 50,000g for 20 min. The supernatant was collected as FA-soluble fractions. All fractions were stored at −80°C until analyzed. Samples were analyzed using hTauspecific ELISA.
hTau-specific ELISA to measure hTau in mouse brain hTau-specific ELISA that was used to measure brain tissue tau was performed as previously described (20) . For assessing hTau in Fig.  4 , biochemical cortical brain extraction samples were analyzed by coating ELISA 96-well plates with the mouse monoclonal anti-tau antibody Tau-5 (20 mg/ml; gift from L. Binder) overnight. Plates were washed five times with PBS and blocked with 4% BSA in PBS for 1 hour at 37°C. Cortical brain extraction samples were diluted in 0.25% BSA in PBS and 300 mM tris (pH 8.0) supplemented with protease inhibitors and kept at 4°C overnight on a shaker. The next day, plates were washed eight times with PBS followed by the addition of mouse monoclonal hTau-specific biotinylated HT7 antibody (0.2 mg/ml; Thermo Scientific) in 1% BSA in PBS for 1.5 hour at 37°C. Next, plates were washed eight times with PBS followed by addition of streptavidin poly-horseradish peroxidase 40 (1:6000; Fitzgerald) for 1.5 hours in the dark at room temperature. Then, plates were washed eight times with PBS and developed with Super Slow ELISA TMB (Sigma-Aldrich), and the absorbance read at 650 nm. For assessing hTau as shown in Fig.  3C , cortical brain extracts from different Tg mice were analyzed by coating ELISA plates with anti-tau antibody BT2 (1 mg/ml) in PBS supplemented with 20% glycerol and incubated overnight at 4°C. Plates were blocked with 2% BSA in PBS supplemented with 0.05% Tween 20 and 20% glycerol for 2 hours at room temperature. Next, the plates were washed four times with PBS followed by the addition of mouse monoclonal hTau-specific biotinylated HT7 antibody (0.2 mg/ml; Thermo Scientific) in 1% BSA in PBS for 1.5 hours at 37°C. Then, plates were washed four times with PBS followed by incubation with streptavidin poly-horseradish peroxidase 40 (1:6000; Fitzgerald) for 1 hour at room temperature. Plates were washed four times with PBS and then developed with Super Slow ELISA TMB (Sigma-Aldrich), and the absorbance read at 650 nm.
qPCR to measure human MAPT RNA in mouse brain tissue For the isolation of RNA, brain tissues were homogenized in TRIzol (Invitrogen). Chloroform was added (1:5 ratio), and samples were vigorously shaken for 15 s at room temperature and then centrifuged at 12,000g for 15 min at 4°C. The aqueous phase of the sample was removed by angling the tube at 45°and pipetting the solution out. Then, samples were diluted (1:1) in 100% isopropanol and incubated for 10 min at room temperature. Samples were centrifuged at 12,000g for 10 min at 4°C. The pellet was washed in 75% ethanol and then centrifuged at 7500g for 10 min. Supernatant was discarded, and the RNA pellet was air-dried for 10 min before resuspension in ribonucleasefree water. Reverse transcription was performed using a high-capacity RNA-to-cDNA kit [Applied Biosystems (ABI)]. qPCR was performed using an ABI TaqMan primer targeting human MAPT (product no. Hs00902194_m1, Life Technologies) and reagents on an ABI Prism 7500 thermocycler, according to the manufacturer's instructions. All mRNA measurements were normalized to the total cDNA.
Microdialysis and 3-NP treatment of P301S Tau Tg mice P301S hippocampal microdialysis was performed in P301S male mice with some modifications (11, 26) . In brief, a microdialysis probe with 100-kDa cutoff (Amuza Inc.) was implanted in the left hippocampus through a guide cannula (Amuza Inc.). Artificial cerebral spinal fluid (ACSF) containing 4% human albumin solution was used as perfusion buffer for ISF collection. ISF was collected in 90-min fractions for 24 hours after probe implantation. Striatal microdialysis with 3-NP treatment was performed in 8-to 9-month-old P301S mice using a microdialysis probe with 1000-kDa cutoff (Amuza Inc.) implanted in the left striatum. ACSF containing 4% human albumin solution was used as perfusion buffer for ISF collection. After stable baseline ISF collection, 200-mM 3-NP (Sigma-Aldrich) was dissolved in perfusion buffer and administered directly in the striatum for 3 hours via reverse microdialysis. For bilateral striatal 3-NP injections combined with plasma tau measurements, a solution of 100 mM 3-NP (Sigma-Aldrich) was prepared in PBS, and 0.5 ml of this solution was injected bilaterally in the striatum of 5-month-old P301S mice via stereotaxic surgery at Bregma coordinates: +0.98 mm, ±1.5 mm mediolateral, and a depth of 2.6 mm, as described (27) .
Statistical analysis
The amount of plasma tau in P301S mice of different ages was compared by two-way ANOVA with post hoc Dunnett's test using GraphPad Prism 6.0 (GraphPad Software). Nonparametric Spearman correlation analyses were performed with GraphPad Prism 6.0 software. The area under the curve (AUC) for tau in plasma during the 24 hours after injection of anti-tau antibody was calculated using the basic noncompartmental pharmacokinetics (PK) package for R (R is a free software environment for statistical computing and graphics). The mean AUCs and error estimates for each group were calculated by PK, and a two-tailed t test was used to determine statistical significance. One-way ANOVA, followed by post hoc Dunnett's test, was used to evaluate the qPCR data, plasma tau half-life data, as well as ISF hTau. Two-way ANOVA with post hoc Dunnett's test was used to evaluate plasma tau measurements from mice administered the neurotoxin 3-NP. Statistical significance was set at P < 0.05. Outliers were determined by performing Grubbs' test using free web GraphPad software. There was one outlier each in the 6-and 9-month-old groups of mice analyzed in Figs. 4 and 5 for plasma and brain tau. All values are presented as means ± SEM.
